{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:42:17Z","timestamp":1761237737910,"version":"3.44.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1053\/j.seminoncol.2010.06.002","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T06:45:34Z","timestamp":1280817934000},"page":"S12-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer"],"prefix":"10.1053","volume":"37","author":[{"given":"Adam M.","family":"Brufsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2007","series-title":"Global cancer facts & figures, 2007","author":"Garcia","key":"10.1053\/j.seminoncol.2010.06.002_bib1"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ctrv.2007.04.005","article-title":"Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?","volume":"33","author":"Ding","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib5","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib9","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"Major","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib11","first-page":"197","article-title":"Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting","volume":"18","author":"Trinkaus","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.7-6-481","article-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy","volume":"7","author":"Major","year":"2002","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/092986708783497346","article-title":"Medical treatment of malignancy-associated hypercalcemia","volume":"15","author":"Lumachi","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib15","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.298.20.2389","article-title":"Factors associated with 5-year risk of hip fracture in postmenopausal women","volume":"298","author":"Robbins","year":"2007","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib17","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","article-title":"Breast cancer","volume":"7","author":"Carlson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","article-title":"Cancer treatment-induced bone loss: pathophysiology and clinical perspectives","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"author":"Eidtmann","key":"10.1053\/j.seminoncol.2010.06.002_bib22"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1359-6349(07)70770-X","article-title":"The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) [abstract]","volume":"5","author":"Schenk","year":"2007","journal-title":"Eur J Cancer Suppl (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib24","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib26","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib27","unstructured":"Shapiro CL, Halabi S, Hars V, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809. Paper presented at: 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30; Chicago, IL."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib28","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib30","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","article-title":"The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer","volume":"84","author":"Saarto","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib33","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib34","doi-asserted-by":"crossref","unstructured":"Van Poznak C, Hannon R, Clack G, et al. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 December 10; San Antonio, TX.","DOI":"10.1158\/0008-5472.SABCS-1137"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib35","first-page":"S9","article-title":"Effect of anastrozole on bone mineral density after one year of treatment: results from the bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract]","volume":"106","author":"Singh","year":"2007","journal-title":"Breast Cancer Res Treat (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib36","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib37","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib38","unstructured":"Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Paper presented at: ASCO 2009 Breast Cancer Symposium; 2009 Oct. 8; San Francisco, CA."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer (review)","volume":"3","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib40","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib45","first-page":"701","article-title":"[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37421","article-title":"Preclinical pharmacology of zoledronic acid","volume":"29","author":"Green","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib48","first-page":"163","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib50","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib52","unstructured":"Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [oral presentation]. Presented at: ECCO 15-34th ESMO Multidisciplinary Congress; 2009 20 September; Berlin, Germany."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib53","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib54","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib57","unstructured":"Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; 2007 December 13; San Antonio, TX."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib58","unstructured":"Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; 2007 December 13; San Antonio, TX."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib59","unstructured":"Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 December 10; San Antonio, TX."},{"key":"10.1053\/j.seminoncol.2010.06.002_bib60","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib61","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib62","first-page":"9","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow\u2014a longtime follow-up [abstract]","volume":"22","author":"Jaschke","year":"2004","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib63","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib64","first-page":"8","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [abstract]","volume":"22","author":"Saarto","year":"2004","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib65","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib66","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib67","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoldronic acid to neoadjuvant chemotherapy on tumor response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib69","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminoncol.2010.06.002_bib70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:56Z","timestamp":1758804776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775410000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":70,"alternative-id":["S0093775410000813"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.06.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}